From: Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence
Patient | Gender | Age | Primary tumor | EOR | Intraoperative ventricle opening | Radiotherapy | Chemotherapy | IDH | TERT promoter | MGMT methylation |
---|---|---|---|---|---|---|---|---|---|---|
1 | Female | 44 | Left frontal lobe | Subtotal | Yes | LBRT 60 Gy/30Fr | TMZ | WT | WT | 0%, Low |
2 | Female | 65 | Left frontal lobe | Partial | Yes | LBRT 60 Gy/30Fr | TMZ | WT | WT | 32.6%, High |
3 | Male | 74 | Left parietal lobe | Total | Yes | LBRT 60 Gy/30Fr | TMZ | WT | WT | 1.3%, Low |
4 | Male | 62 | Left thalamus | Biopsy | No | LBRT 60 Gy/30Fr | TMZ | WT | WT | 3.7%, Low |
5 | Male | 69 | Right temporal lobe | Subtotal | Yes | LBRT 60 Gy/30Fr | TMZ Nivolumab | WT | C228T | 39.9%, High |
6 | Male | 73 | Left temporal lobe | Total | Yes | LBRT 60 Gy/30Fr | TMZ | WT | C228T | 0.8%, Low |